{"id":70733,"date":"2026-05-12T10:13:05","date_gmt":"2026-05-12T10:13:05","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70733"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"ghrp-6","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/ghrp-6\/","title":{"rendered":"GHRP-6 Ac\u00e9tate"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'ac\u00e9tate de GHRP-6 ?<\/h3>\n<p style=\"margin: 0;\"><strong>GHRP-6 Ac\u00e9tate<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the original growth hormone secretagogues, developed by Bowers and colleagues as the second-generation member of the GHRP series. It acts on the growth hormone secretagogue receptor (GHS-R1a) \u2014 the same receptor as endogenous ghrelin \u2014 producing pulsatile GH release alongside appetite stimulation. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">87616-84-0 (base libre de GHRP-6) ; fourni sous forme de sel d'ac\u00e9tate<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub> (base libre ; le sel d'ac\u00e9tate ajoute un contre-ion CH<sub>3<\/sub>COOH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">873,02 Da (base libre)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2<\/sub> (HwAWfK-NH<sub>2<\/sub>, 6 acides amin\u00e9s ; contient du D-Trp en position 2 et du D-Phe en position 5 pour une stabilit\u00e9 prot\u00e9olytique ; amidation en C-terminal)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sel d'ac\u00e9tate lyophilis\u00e9 (poudre blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'ac\u00e9tate de GHRP-6 ?<\/h2>\n<p><strong>GHRP-6<\/strong> (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the canonical members of the growth hormone secretagogue (GHS) peptide class. It was developed by Cyril Y. Bowers and colleagues at Tulane University as part of a structure-activity relationship programme designed to identify small peptides capable of stimulating pulsatile growth hormone release from the anterior pituitary \u2014 work that ultimately led to the discovery of the growth hormone secretagogue receptor and, indirectly, to the identification of endogenous ghrelin as its natural ligand in 1999 by Kojima et al. (Nature). The acetate counterion is used in pharmaceutical-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology. The well-characterised sequence is HwAWfK-NH<sub>2<\/sub> (o\u00f9 les lettres minuscules d\u00e9signent des r\u00e9sidus d'acides amin\u00e9s D), poids mol\u00e9culaire 873,02 Da, formule empirique C<sub>46<\/sub>H<sub>56<\/sub>N<sub>12<\/sub>O<sub>6<\/sub>. Les deux substitutions d'acides amin\u00e9s D (D-Trp en position 2 et D-Phe en position 5) conf\u00e8rent une r\u00e9sistance aux prot\u00e9ases endog\u00e8nes et prolongent la demi-vie in vivo par rapport aux analogues tout-L. Le C-terminal est amid\u00e9, ce qui est essentiel pour l'activit\u00e9 r\u00e9ceptrice. Le GHRP-6 n'est <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the newer-generation receptor-selective analog without cortisol\/prolactin signalling, see our <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> page produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Agonisme du r\u00e9cepteur GHS-R1a et la pulsation de GH<\/h2>\n<p>What makes GHRP-6 mechanistically distinctive among growth-axis peptides is its <strong>action s\u00e9lective sur le r\u00e9cepteur des s\u00e9cr\u00e9tagogues de l'hormone de croissance<\/strong> \u2014 the same receptor activated by endogenous ghrelin \u2014 rather than the GHRH receptor used by sermorelin and CJC-1295. The downstream effect is a pulsatile rather than tonic pattern of GH release in published studies:<\/p>\n<ul>\n<li><strong>Agonisme du r\u00e9cepteur GHS-R1a sur les somatotropes<\/strong> \u2014 Le GHRP-6 se lie au r\u00e9cepteur des s\u00e9cr\u00e9tagogues de l'hormone de croissance de type 1a (GHS-R1a, \u00e9galement appel\u00e9 r\u00e9cepteur de la ghr\u00e9line) sur les somatotropes de l'hypophyse ant\u00e9rieure. L'activation du r\u00e9cepteur couple \u00e0 G\u03b1<sub>q\/11<\/sub> et \u00e0 la phospholipase C, augmentant le calcium intracellulaire et d\u00e9clenchant l'exocytose coupl\u00e9e \u00e0 la d\u00e9polarisation des v\u00e9sicules contenant de l'hormone de croissance (GH). Le signal est amplifi\u00e9 par la suppression du tonus somatostatine \u2014 le GHRP-6 agit \u00e0 la fois sur les somatotropes et sur les neurones \u00e0 somatostatine hypothalamiques, produisant une impulsion de GH plus importante que ne le pr\u00e9voirait la stimulation directe des somatotropes seule.<\/li>\n<li><strong>Synergie avec la GHRH endog\u00e8ne<\/strong> \u2014 Les voies GHS-R et GHRH-R convergent intracellulairement mais utilisent des syst\u00e8mes de seconds messagers diff\u00e9rents (PLC\/IP<sub>3<\/sub>Puis-je commander de l'ac\u00e9tate d'ocytocine pour une livraison internationale ?<sup>2+<\/sup> vs adenylyl cyclase\/cAMP\/PKA), so GHRP-6 and GHRH analogs produce additive or synergistic GH release when combined. This is the rationale for the canonical &#8220;GHRP + GHRH analog&#8221; studies combinations: a GHS such as GHRP-6 paired with a GHRH analog such as <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a>. Le stimulus combin\u00e9 produit des impulsions de GH nettement plus importantes que chaque compos\u00e9 seul.<\/li>\n<li><strong>Stimulation de l'app\u00e9tit hors cible et signal modeste de cortisol\/prolactine<\/strong> \u2014 Because GHRP-6 acts on the ghrelin receptor, it inherits ghrelin&#8217;s appetite-stimulating effect \u2014 useful in cachexia studies, but a confound in cleaner GH-axis pharmacology. GHRP-6 also produces a modest increase in cortisol and prolactin secretion. The newer-generation selective analog Ipamorelin was specifically designed to eliminate this cortisol\/prolactin signal while preserving the GH effect \u2014 see the comparison section below.<\/li>\n<\/ul>\n<p>GHRP-6 has a plasma half-life of approximately 30\u201360 minutes, considerably longer than native ghrelin (~10\u201330 minutes) due to the D-amino-acid substitutions that resist proteolytic cleavage. Subcutaneous administration is the most-cited administration route in the published literature; intravenous and intranasal routes are also documented in mechanism-of-action studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>GHRP-6 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmacologie de l'axe de l'hormone de croissance<\/strong> \u2014 pulsatile GH dynamics, somatotroph responsiveness, comparative GH-secretagogue studies; benchmark first-generation GHS in published GH-pulse architecture studies (Bowers et al., J Clin Endocrinol Metab; Smith et al., Science 1996)<\/li>\n<li><strong>Appetite and feeding behaviour studies<\/strong> \u2014 ghrelin-axis activation, food-intake assays in rodent models, cachexia models in tumour-bearing animals; canonical tool for separating ghrelin-mediated orexigenic signalling from other appetite pathways<\/li>\n<li><strong>Pituitary function studies<\/strong> \u2014 GH reserve testing in preclinical models, somatotroph hypertrophy \/ hyperplasia, mechanism-of-action data for novel GH secretagogues<\/li>\n<li><strong>Cachexia and wasting syndrome<\/strong> \u2014 cachexie chez les rongeurs porteurs de tumeurs, mod\u00e8les de d\u00e9p\u00e9rissement associ\u00e9 \u00e0 la BPCO, pr\u00e9servation de la masse maigre\/masse grasse par activation combin\u00e9e de l'axe GH et de l'axe de l'app\u00e9tit<\/li>\n<li><strong>Comparative GHS studies<\/strong> \u2014 benchmarking direct contre de nouveaux analogues, y compris <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> (s\u00e9lectif des r\u00e9cepteurs sans cortisol\/prolactine), hexar\u00e9line (GHRP-6 modifi\u00e9), GHRP-2 (analogue de premi\u00e8re g\u00e9n\u00e9ration alternatif) et petits mol\u00e9cules GHS actives par voie orale comme le MK-677<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 GHS-R expression on cardiomyocytes; published studies on cardiac ischaemia-reperfusion injury and cardiac function in GH-deficient models<\/li>\n<li><strong>Combined GHRP + GHRH use<\/strong> \u2014 protocoles synergiques de lib\u00e9ration de GH associant GHRP-6 \u00e0 des analogues de GHRH tels que <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for maximal pulsatile GH studies stimulus.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place du GHRP-6 dans le paysage des peptides de l'axe de croissance, voir <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> en tant qu'analogue s\u00e9lectif des r\u00e9cepteurs de nouvelle g\u00e9n\u00e9ration, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for long-acting GHRH-axis studies, and <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks GHRP-6 Acetate in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 short-cycle GH-pulse protocols, single-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles \u00e0 cycle prolong\u00e9, \u00e9tudes \u00e0 cohortes multiples, co\u00fbt le plus bas par mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. Because GHRP-6 dose ranges are in the 50\u2013300\u00a0mcg per administration regime, a single 5\u00a0mg vial supports many weeks of use at typical doses. <\/p>\n<h2>Comparaison \u2014 GHRP-6 vs Ipamorelin<\/h2>\n<p>Le GHRP-6 et <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> are the canonical first- and third-generation members of the growth hormone secretagogue peptide class, respectively, and are the most-cited head-to-head comparison in published GHS studies. They share the same receptor (GHS-R1a) and produce comparable GH pulses, but differ substantially in receptor selectivity and off-target signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHRP-6<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Ipamorelin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">6 acides amin\u00e9s (hexapeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5 acides amin\u00e9s (pentapeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>G\u00e9n\u00e9ration<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de premi\u00e8re g\u00e9n\u00e9ration (~1984)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS de troisi\u00e8me g\u00e9n\u00e9ration (~1998)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>R\u00e9cepteur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (r\u00e9cepteur de la ghr\u00e9line)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHS-R1a (r\u00e9cepteur de la ghr\u00e9line)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Pulsation de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lib\u00e9ration pulsatile importante de GH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lib\u00e9ration pulsatile importante de GH (comparable au GHRP-6)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Signal d'app\u00e9tit<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui (effet orexig\u00e8ne similaire \u00e0 la ghr\u00e9line)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Minimal or absent in published studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cortisol \/ prolactine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modest increases (studies-relevant confound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucune augmentation mesurable \u2014 le gain cl\u00e9 en s\u00e9lectivit\u00e9<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">50\u2013300 mcg, 1\u20133 fois par jour<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013300 mcg, 1\u20133 fois par jour<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30\u201360 min<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2 heures<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies where the appetite-stimulation signal is a feature (cachexia models, food-intake studies), GHRP-6 is preferred because the orexigenic effect is part of the studies target. For clean GH-axis pharmacology where cortisol and prolactin are confounding variables, Ipamorelin is preferred because the receptor-selectivity gains eliminate those off-target signals. Both are frequently paired with a GHRH analog (such as <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a>) for the canonical synergistic GH-pulse support protocol. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon de peptide (pas directement sur le g\u00e2teau lyophilis\u00e9). Pour un flacon de 5 mg, 2,0 mL d'eau bact\u00e9riostatique donnent une concentration de travail de 2,5 mg\/mL \u2014 0,04 mL d\u00e9livre une dose de recherche de 100 mcg ; 0,1 mL d\u00e9livre 250 mcg. Agitez doucement \u2014 ne pas. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose; 0.1\u00a0mL delivers 250\u00a0mcg. Swirl gently \u2014 do <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore. <strong>Apr\u00e8s reconstitution :<\/strong> conservez au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les cycles de gel-d\u00e9gel d\u00e9gradent l'int\u00e9grit\u00e9 du peptide. Jetez tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is GHRP-6 used for in studies?<\/h3>\n<p>GHRP-6 is used in studies investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph responsiveness, ghrelin-axis pharmacology, appetite and feeding behaviour, cachexia and wasting syndromes, and combined GHRP + GHRH synergistic GH-release protocols. It is the canonical first-generation GHS peptide and the structural template from which Ipamorelin and other later-generation analogs were derived. The pharmaceutical-grade GHRP-6 sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi le GHRP-6 diff\u00e8re-t-il de l'Ipamorelin ?<\/h3>\n<p>Both act on the same receptor (GHS-R1a, the ghrelin receptor) and produce comparable pulsatile GH release, but they differ substantially in receptor selectivity and off-target signalling. GHRP-6 produces ghrelin-like appetite stimulation and modest increases in cortisol and prolactin. Ipamorelin was specifically designed to eliminate these off-target signals while preserving the GH effect \u2014 it produces minimal appetite signal and no measurable cortisol or prolactin increase in published studies. For clean GH-axis pharmacology, Ipamorelin is preferred; for studies involving appetite as a target, GHRP-6 remains useful. <\/p>\n<h3>Quelle est la diff\u00e9rence entre le GHRP-6 et le GHRP-2 ?<\/h3>\n<p>Both are first-generation hexapeptide growth hormone secretagogues from the Bowers clinical programme. GHRP-2 is somewhat more potent on a per-mg basis and produces slightly less appetite signal than GHRP-6, but the qualitative pharmacology is similar \u2014 both raise cortisol and prolactin modestly. GHRP-6 is the more extensively studied of the pair in published studies and remains the canonical first-generation reference compound. <\/p>\n<h3>What is the typical GHRP-6 dose?<\/h3>\n<p>Published preclinical protocols typically use 50\u2013300\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 2\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.1\u00a0mL equals 250\u00a0mcg. <\/p>\n<h3>Le GHRP-6 est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. GHRP-6 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h3>Comment doit \u00eatre conserv\u00e9 l'ac\u00e9tate de GHRP-6 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : conserv\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C pour les stocks de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : conserv\u00e9e au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer le GHRP-6 ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> Secouez le flacon. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 2,0 mL de diluant, la concentration de travail est de 2,5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries GHRP-6 Acetate in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi le GHRP-6 stimule-t-il \u00e9galement l'app\u00e9tit ?<\/h3>\n<p>Le GHRP-6 se lie au r\u00e9cepteur des s\u00e9cr\u00e9tagogues de l'hormone de croissance (GHS-R1a) \u2014 le m\u00eame r\u00e9cepteur activ\u00e9 par la ghr\u00e9line endog\u00e8ne. Comme la ghr\u00e9line est la principale hormone de la faim, tout agoniste de son r\u00e9cepteur h\u00e9rite d'une certaine activit\u00e9 orexig\u00e8ne (stimulatrice de l'app\u00e9tit). Pour les GHS de premi\u00e8re g\u00e9n\u00e9ration comme le GHRP-6 et le GHRP-2, l'effet sur l'app\u00e9tit est important ; pour les analogues s\u00e9lectifs de r\u00e9cepteurs de g\u00e9n\u00e9ration ult\u00e9rieure comme l'Ipamor\u00e9line, le signal orexig\u00e8ne a \u00e9t\u00e9 att\u00e9nu\u00e9 avec succ\u00e8s gr\u00e2ce \u00e0 une optimisation structurelle. <\/p>\n<h3>Can GHRP-6 be paired with a GHRH analog in studies?<\/h3>\n<p>Yes \u2014 this is the canonical synergistic GH-pulse support protocol. GHRP-6 activates GHS-R1a (PLC\/IP<sub>3<\/sub>Puis-je commander de l'ac\u00e9tate d'ocytocine pour une livraison internationale ?<sup>2+<\/sup> Le GHRP-6 provoque-t-il des effets secondaires dans la recherche ? <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> ou <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> active le r\u00e9cepteur GHRH (signalisation ad\u00e9nylyl cyclase\/AMPc\/PKA). Les deux voies convergent vers les somatotrophes mais utilisent des syst\u00e8mes de seconds messagers diff\u00e9rents, produisant une lib\u00e9ration de GH additive ou synergique lorsqu'elles sont combin\u00e9es. <\/p>\n<h3>Does GHRP-6 cause side reported effects?<\/h3>\n<p>The principal on-target effects are GH release and appetite stimulation. Off-target findings include modest cortisol and prolactin increases (the principal studies-relevant confound for GH-axis studies), transient flushing or local injection-site reactions, and (rarely) GHS-R-mediated effects on cardiac function at high doses. The cortisol\/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed. <\/p>\n<h3>Quelle est la demi-vie du GHRP-6 ?<\/h3>\n<p>In preclinical studies, GHRP-6 has a plasma half-life of approximately 30\u201360 minutes following subcutaneous administration. The extended half-life relative to endogenous ghrelin (~10\u201330 min) is due to the two D-amino-acid substitutions (D-Trp at position 2 and D-Phe at position 5) that resist proteolytic cleavage. The GH pulse outlasts plasma clearance because somatotroph desensitisation and receptor downregulation are slower processes. <\/p>\n<h3>How long does GHRP-6 take to show effects in preclinical studies?<\/h3>\n<p>Les pics aigus de GH sont d\u00e9tectables dans les 15 \u00e0 30 minutes suivant l'administration sous-cutan\u00e9e et atteignent leur maximum en 60 \u00e0 90 minutes. Les effets stimulants sur l'app\u00e9tit et la prise alimentaire sont mesurables dans les heures suivant l'administration dans les mod\u00e8les murins. Les effets en aval sur la production d'IGF-1 et la signalisation de l'axe GH au niveau tissulaire s'accumulent sur 1 \u00e0 4 semaines de dosage r\u00e9gulier. <\/p>\n<h3>Puis-je commander du GHRP-6 pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le GHRP-6 dans le monde entier depuis notre r\u00e9seau d\u00e9di\u00e9 \u00e0 l'exp\u00e9dition de peptides. Les commandes contenant uniquement des peptides sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition d\u00e9di\u00e9. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Pentapeptide GHS s\u00e9lectif de troisi\u00e8me g\u00e9n\u00e9ration \u2014 pulse de GH propre sans cortisol\/prolactine<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical GHRH-axis compound<\/li>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/fr\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Analogue recombinant IGF-1 \u00e0 longue arginine \u2014 en aval de l'axe GH\/IGF<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explorez le paysage des peptides de l'axe GH<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s de l'axe GH incluant <a href=\"https:\/\/medsbase.com\/fr\/ipamorelin\/\">Ipamorelin<\/a> for clean receptor-selective GHS studies, <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> for natural-pulse GHRH use.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Hexapeptide GHS de premi\u00e8re g\u00e9n\u00e9ration<br \/>\n\u2705 Agoniste du r\u00e9cepteur GHS-R1a\/ghr\u00e9line<br \/>\n\u2705 Stimule la lib\u00e9ration pulsatile de GH<br \/>\n\u2705 Ghrelin-axis appetite studies<br \/>\n\u2705 Synergie avec les analogues de GHRH<\/p>\n<p><strong>GHRP-6 Ac\u00e9tate<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70956,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6280,5441],"class_list":["post-70733","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ghrp-6","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70733","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70956"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70733"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70733"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70733"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}